接受抗逆转录病毒治疗的HIV感染者病毒学反弹状态的影响因素及不良后果
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.
作者信息
Yuan Defu, Li Mingma, Zhou Ying, Shi Lingen, Lu Jing, Fu Gengfeng, Wang Bei
机构信息
Department of Epidemiology and Health Statistics, Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing, China.
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
出版信息
J Virus Erad. 2023 Mar 4;9(1):100320. doi: 10.1016/j.jve.2023.100320. eCollection 2023 Mar.
Abstract
Antiretroviral therapy (ART) aims to inhibit HIV replication, decrease CD4 T cell loss, and immune function recovery in order to reduce the morbidity and mortality associated with the infection. Treatment should also, improve quality of life and control HIV spread. However, incomplete viral suppression still occurs during ART. Viral suppression and virological failure (VF) thresholds vary between studies in terms of virological rebound (VR) states using different detection thresholds. Further understanding of influencing factors and adverse outcomes in various VR states should provide important guidance for HIV treatment.
摘要
抗逆转录病毒疗法（ART）旨在抑制HIV复制，减少CD4 T细胞损失，并恢复免疫功能，以降低与该感染相关的发病率和死亡率。治疗还应改善生活质量并控制HIV传播。然而，在ART期间仍会出现病毒抑制不完全的情况。在使用不同检测阈值的病毒学反弹（VR）状态方面，不同研究的病毒抑制和病毒学失败（VF）阈值有所不同。进一步了解各种VR状态下的影响因素和不良后果应为HIV治疗提供重要指导。
相似文献
1
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.
J Virus Erad. 2023 Mar 4;9(1):100320. doi: 10.1016/j.jve.2023.100320. eCollection 2023 Mar.
2
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
J Antimicrob Chemother. 2016 Apr;71(4):1051-5. doi: 10.1093/jac/dkv433. Epub 2015 Dec 24.
3
Molecular biological assessment methods and understanding the course of the HIV infection.
APMIS Suppl. 2003(114):1-37.
4
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
HIV Med. 2017 Mar;18(3):196-203. doi: 10.1111/hiv.12413. Epub 2016 Aug 1.
5
Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
Clin Infect Dis. 2023 Jan 6;76(1):25-31. doi: 10.1093/cid/ciac762.
6
Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy.
mBio. 2021 Mar 9;12(2):e00099-21. doi: 10.1128/mBio.00099-21.
7
Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
HIV Med. 2022 Mar;23 Suppl 1:72-83. doi: 10.1111/hiv.13251.
8
A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
S Afr Med J. 2020 Mar 30;110(4):313-319. doi: 10.7196/SAMJ.2020.v110i4.13934.
9
Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
AIDS Rev. 2018 Jan-Mar;20(1):71-72.
10
Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression.
AIDS. 2019 Nov 1;33(13):1987-1994. doi: 10.1097/QAD.0000000000002307.
引用本文的文献
1
Association between baseline HIV-1 DNA levels and clinical outcomes in people living with HIV: a meta-analysis of cohort studies.
Emerg Microbes Infect. 2025 Dec;14(1):2508759. doi: 10.1080/22221751.2025.2508759. Epub 2025 May 28.
2
Assessing HIV-1 subtype C infection dynamics, therapeutic responses and reservoir distribution using a humanized mouse model.
Front Immunol. 2025 Apr 16;16:1552563. doi: 10.3389/fimmu.2025.1552563. eCollection 2025.
3
Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines.
AIDS. 2025 Jul 1;39(8):1024-1031. doi: 10.1097/QAD.0000000000004144. Epub 2025 Feb 4.
4
Detectable Virological Load and Associated Factors among People Living with HIV on Antiretroviral Treatment: A Retrospective Study.
Pathogens. 2024 Apr 27;13(5):359. doi: 10.3390/pathogens13050359.
5
Prevalence and predictors of persistent low-level HIV viraemia: a retrospective cohort study among people receiving dolutegravir-based antiretroviral therapy in Southern Nigeria.
Ther Adv Infect Dis. 2024 Apr 2;11:20499361241242240. doi: 10.1177/20499361241242240. eCollection 2024 Jan-Dec.
6
The association of changes in depression severity after the onset of the COVID-19 pandemic and viral nonsuppression among people with HIV.
AIDS. 2024 May 1;38(6):887-894. doi: 10.1097/QAD.0000000000003828. Epub 2023 Dec 29.
7
Prevention and Control Are Not a Regional Matter: A Spatial Correlation and Molecular Linkage Analysis Based on Newly Reported HIV/AIDS Patients in 2021 in Jiangsu, China.
Viruses. 2023 Oct 6;15(10):2053. doi: 10.3390/v15102053.
8
Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study.
Viruses. 2023 Aug 12;15(8):1727. doi: 10.3390/v15081727.
本文引用的文献
1
Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
HIV Med. 2022 Mar;23 Suppl 1:64-71. doi: 10.1111/hiv.13250.
2
Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
HIV Med. 2022 Mar;23 Suppl 1:72-83. doi: 10.1111/hiv.13251.
3
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
HIV Med. 2022 Sep;23(8):825-836. doi: 10.1111/hiv.13265. Epub 2022 Mar 1.
4
HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana.
J Antimicrob Chemother. 2022 Apr 27;77(5):1385-1395. doi: 10.1093/jac/dkac056.
5
Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
J Glob Antimicrob Resist. 2022 Jun;29:7-16. doi: 10.1016/j.jgar.2022.02.007. Epub 2022 Feb 13.
6
Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy.
J Acquir Immune Defic Syndr. 2022 Apr 15;89(5):575-582. doi: 10.1097/QAI.0000000000002898.
7
Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India.
Indian J Sex Transm Dis AIDS. 2021 Jan-Jun;42(1):31-37. doi: 10.4103/ijstd.IJSTD_34_20. Epub 2021 May 3.
8
Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China.
Infect Drug Resist. 2021 Nov 2;14:4529-4537. doi: 10.2147/IDR.S332924. eCollection 2021.
9
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV.
Open Forum Infect Dis. 2021 Sep 17;8(9):ofab463. doi: 10.1093/ofid/ofab463. eCollection 2021 Sep.
10
Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study.
Medicine (Baltimore). 2021 Sep 3;100(35):e26817. doi: 10.1097/MD.0000000000026817.
Zotero 插件